Metabolic Sx May Up CRC Risk Even in Healthy-Weight Women

Share this content:
Metabolic Sx May Up CRC Risk Even in Healthy-Weight Women
Metabolic Sx May Up CRC Risk Even in Healthy-Weight Women

WEDNESDAY, Feb. 1, 2017 (HealthDay News) -- Even normal-weight women may be at greater risk for colorectal cancer if they have certain traits, such as elevated triglycerides, low high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting glucose, according to a study published online Feb. 1 in Cancer Epidemiology, Biomarkers & Prevention.

The study involved normal-weight postmenopausal women, aged 50 to 79. The research team's analysis involved 5,068 women enrolled in the Women's Health Initiative, a 15-year study led by the U.S. National Institutes of Health.

One-third of the women in the study were deemed metabolically unhealthy, meaning they had two or more risk factors of metabolic syndrome (excluding waist measurement). The researchers found that normal-weight women who were metabolically unhealthy had an increased risk of colorectal cancer (hazard ratio, 1.49; 95 percent confidence interval, 1.02 to 2.18), compared with metabolically-healthy women.

"A metabolically unhealthy phenotype was associated with higher risk of colorectal cancer among normal-weight women," the authors write. "Normal-weight women should still be evaluated for metabolic health and appropriate steps taken to reduce their risk of colorectal cancer."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »